Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting
Frontiers in Oncology · 29.11.2024 · 14
DOI: 10.3389/fonc.2024.1395502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 29.11.2024. Verfasst von Brendan Moloney und 24 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Quantitative dynamic contrast-enhanced (DCE) MRI as a promising method for the prediction of breast cancer response to neoadjuvant chemotherapy (NAC) has been demonstrated mostly in single-center and single-vendor platform studies. This preliminary study reports the initial experience in implementing quantitative breast DCE-MRI in multi-center (MC) and multi-vendor platform (MP) settings to predict NAC response. MRI data, including B 1 mapping, variable flip angle (VFA) measurements of native tissue R 1 (R 1,0 ), and DCE-MRI, were acquired during NAC at three sites using 3T systems with Siemens, Philips, and GE platforms, respectively. High spatiotemporal resolution DCE-MRI was performed using similar vendor product sequences with k-space undersampling during acquisition and view sharing during reconstruction. A breast phantom was used for quality assurance/quality control (QA/QC) across sites. The Tofts model (TM) and shutter-speed model (SSM) were used for pharmacokinetic (PK) analysis of the DCE data. Additionally, tumor region of interest (ROI)- vs . voxel-based analyses in combination with the use of VFA-measured R 1,0 vs . fixed, literature-reported R 1,0 were investigated to determine the optimal analysis approach. Results from 15 patients who completed the study are reported. Voxel-based PK analysis using fixed R 1,0 was deemed the optimal approach, which allowed the inclusion of data from one vendor platform where VFA measurements produced ≥100% overestimation of R 1,0 . The semi-quantitative signal enhancement ratio (SER) and quantitative PK parameters outperformed the tumor longest diameter (LD) in the prediction of pathologic complete response (pCR) vs. non-pCR after the first NAC cycle, whereas K trans consistently provided more accurate predictions than both SER and LD after the first NAC cycle and at the NAC midpoint. Both TM and SSM K trans and k ep were excellent predictors of response at the NAC midpoint with ROC AUC >0.90, while the SSM parameters (AUC ≥0.80) performed better than their TM counterparts (AUC <0.80) after the first NAC cycle. The initial experience of this ongoing study indicates the importance of QA/QC using a phantom and suggests that deploying voxel-based PK analysis using a fixed R 1,0 may mitigate random errors from R 1,0 measurements across platforms and potentially eliminate the need for B 1 and VFA acquisitions in MC and MP trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR, United States.
- Department of Radiology, University of Washington, Seattle, WA, United States.
- Department of Radiology, University of Iowa, Iowa City, IA, United States.
- Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, United States.
- Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR, United States.
- Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA, United States.
Förderung
- NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Moloney, B., Li, X., Hirano, M., Saad Eddin, A., Lim, J. Y., Biswas, D., Kazerouni, A. S., Tudorica, A., Li, I., Bryant, M. L., Wille, C., Pyle, C., Rahbar, H., Hsieh, S. K., Rice-Stitt, T. L., Dintzis, S. M., Bashir, A., Hobbs, E., Zimmer, A., …, & Huang, W. (2024). Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1395502
Vancouver
Moloney B, Li X, Hirano M, Saad Eddin A, Lim JY, Biswas D, et al. Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1395502
BibTeX
@article{Moloney2024,
author = {Moloney, Brendan and Li, Xin and Hirano, Michael and Saad Eddin, Assim and Lim, Jeong Youn and Biswas, Debosmita and Kazerouni, Anum S and Tudorica, Alina and Li, Isabella and Bryant, Mary Lynn and Wille, Courtney and Pyle, Chelsea and Rahbar, Habib and Hsieh, Su Kim and Rice-Stitt, Travis L and Dintzis, Suzanne M and Bashir, Amani and Hobbs, Evthokia and Zimmer, Alexandra and Specht, Jennifer M and Phadke, Sneha and Fleege, Nicole and Holmes, James H and Partridge, Savannah C and Huang, Wei},
title = {Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1395502}
}
EUVIMED